• myGriffith
    • Staff portal
    • Contact Us⌄
      • Future student enquiries 1800 677 728
      • Current student enquiries 1800 154 055
      • International enquiries +61 7 3735 6425
      • General enquiries 07 3735 7111
      • Online enquiries
      • Staff phonebook
    View Item 
    •   Home
    • Griffith Research Online
    • Conference outputs
    • View Item
    • Home
    • Griffith Research Online
    • Conference outputs
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

  • All of Griffith Research Online
    • Communities & Collections
    • Authors
    • By Issue Date
    • Titles
  • This Collection
    • Authors
    • By Issue Date
    • Titles
  • Statistics

  • Most Popular Items
  • Statistics by Country
  • Most Popular Authors
  • Support

  • Contact us
  • FAQs
  • Admin login

  • Login
  • Value for money of putting precision into practice: Germline genetic testing to guide olaparib treatment in HER2-negative metastatic breast cancer

    Author(s)
    Tuffaha, Haitham
    Scuffham, Paul
    Griffith University Author(s)
    Scuffham, Paul A.
    Year published
    2019
    Metadata
    Show full item record
    Abstract
    Aim: Genetic testing for germline BRCA mutation in women with HER2‐negative metastatic breast cancer (MBC) can guide targeted treatment with poly‐ADP‐ribose polymerase (PARP) inhibitors (eg olaparib) and inform cancer prevention strategies (eg risk‐reducing surgery) for family members of women who test positive. This study aimed to evaluate the cost‐effectiveness of BRCA testing in women with MBC to inform olaparib treatment and cascade testing of family members. Methods: A cost‐effectiveness analysis was conducted using a decision analytic model from an Australian health‐payer perspective. Two scenarios were evaluated ...
    View more >
    Aim: Genetic testing for germline BRCA mutation in women with HER2‐negative metastatic breast cancer (MBC) can guide targeted treatment with poly‐ADP‐ribose polymerase (PARP) inhibitors (eg olaparib) and inform cancer prevention strategies (eg risk‐reducing surgery) for family members of women who test positive. This study aimed to evaluate the cost‐effectiveness of BRCA testing in women with MBC to inform olaparib treatment and cascade testing of family members. Methods: A cost‐effectiveness analysis was conducted using a decision analytic model from an Australian health‐payer perspective. Two scenarios were evaluated compared with no testing and standard chemotherapy: (a) BRCA testing of women with MBC followed by olaparib if the test is positive; and (b) BRCA testing of women with MBC followed by olaparib and cascade testing of first‐ and second‐degree family members if the test is positive. For each scenario, the incremental cost was compared with the quality‐adjusted life‐years (QALYs) gained to estimate the incremental cost‐effectiveness ratio (ICER). Decision uncertainty was characterised using probabilistic sensitivity analysis. Results: Scenario 1 resulted in an incremental cost of AU$11 607 and 0.04 QALYs gained (ICER = AU$277 000/QALY), whereas Scenario 2 resulted in an incremental cost of AU$12 575 and 0.12 QALYs gained (ICER = AU$105 000/QALY). At a willingness‐to‐pay threshold of AU$100 000/QALY and at the listed price of olaparib, none of the scenarios were cost‐effective. Probability of being cost‐effective was 0% and 40% for Scenario 1 and Scenario 2, respectively. Nevertheless, if olaparib price is significantly reduced by 60%, the two scenarios would become cost‐effective, with Scenario 2 offering an additional AU$1100 in mean monetary benefit over Scenario 1. Conclusions: Genetic testing for BRCA germline mutation to guide olaparib treatment in women with MBC is not cost‐effective unless the price of olaparib is significantly reduced. Extending BRCA testing to cover family members of mutation carriers would provide additional benefits compared with testing affected women only.
    View less >
    Conference Title
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
    Volume
    15
    Issue
    S9
    DOI
    https://doi.org/10.1111/ajco.13262
    Subject
    Oncology and carcinogenesis
    Science & Technology
    Life Sciences & Biomedicine
    Publication URI
    http://hdl.handle.net/10072/392667
    Collection
    • Conference outputs

    Footer

    Disclaimer

    • Privacy policy
    • Copyright matters
    • CRICOS Provider - 00233E
    • TEQSA: PRV12076

    Tagline

    • Gold Coast
    • Logan
    • Brisbane - Queensland, Australia
    First Peoples of Australia
    • Aboriginal
    • Torres Strait Islander